This clinical trial is focused on studying the effects of certain medications on patients with ulcerative colitis, a chronic condition that causes inflammation and sores in the digestive tract. The medications being studied include adalimumab (also known as AMGEVITA), tofacitinib (known as XELJANZ), vedolizumab (known as Entyvio), infliximab (known as Inflectra), and golimumab (known as Simponi). These treatments are being evaluated for their impact on heart and blood vessel health, specifically looking at how they affect the stiffness of the aorta, the thickness of the carotid artery walls, and overall cardiovascular risk.

The purpose of the study is to compare the changes in the thickness of the carotid artery walls after three months of treatment with these medications in patients with ulcerative colitis. Participants will receive one of the medications or a placebo and will be monitored over a period of time to assess the effects on their cardiovascular health. The study will also look at other factors such as blood pressure, cholesterol levels, and the activity of ulcerative colitis symptoms.

Throughout the study, participants will undergo various assessments to measure the impact of the treatments on their cardiovascular health and ulcerative colitis symptoms. These assessments will include checking the thickness of the carotid artery walls, measuring the stiffness of the arteries, and evaluating the risk of cardiovascular disease. The study aims to provide valuable insights into how these medications can affect heart and blood vessel health in patients with ulcerative colitis.